New partnership to fast-track Canadian health technology from innovation to patient care




New partnership to fast-track Canadian health technology from innovation to patient care

AIM Institute and CAN Health Network join forces to help 
Canadian solutions reach clinicians and patients faster

NEW WESTMINSTER, British Columbia, March 19, 2026 (GLOBE NEWSWIRE) — Royal Columbian Hospital Foundation’s AIM Institute (Advancing Innovation in Medicine) has partnered with the CAN Health Network to collaborate in supporting and scaling promising Canadian health technologies – helping patients benefit sooner from made-in-Canada solutions.

This collaboration brings together two Canadian organizations with a shared commitment to strengthening patient care through innovation. By aligning AIM’s clinical expertise and trial infrastructure with the CAN Health Network’s national network of health care operators and procurement pathways, the partnership is designed to help Canadian health-tech companies move faster from idea to validated solution, and ultimately to broader adoption across Canada.

Canadian health-tech companies will benefit from access to user-defined clinical challenges, direct engagement with frontline clinicians, rigorous clinical trial design and execution, and real-world product evaluation. The goal is to ensure that new solutions are not only innovative, but also clinically validated, economically viable, and ready for scale within Canada’s health care system.

As a social enterprise of Royal Columbian Hospital Foundation, AIM Institute partners with health-tech innovators at every stage of development, from early clinical guidance to multi-centre trials and real-world implementation. Its work is grounded in the belief that improving patient care and achieving commercial success are intrinsically linked.

The CAN Health Network connects healthcare organizations across the country through an integrated market to identify challenges, validate Canadian solutions in real-world settings, and support procurement and scale. Since its launch in 2019, CAN Health has supported commercialization projects with more than 100 Canadian companies, helping strengthen health care delivery while driving economic growth.

“Working alongside the CAN Health Network allows us to help promising Canadian technologies move more efficiently from concept to real-world use,” says Dr. Steve Reynolds, Royal Columbian Hospital ICU physician and AIM Executive Lead. “This helps ensure that solutions developed here can ultimately improve care for patients and support healthcare teams across the country and beyond.”

“The most powerful health care solutions come from solving real problems faced by patients and providers,” said Dante Morra, Founder & CEO, CAN Health Network. “By connecting innovators with frontline health care environments through the AIM Institute, we can test, validate and scale Canadian solutions faster, improving care while helping Canadian companies grow and succeed.”

This partnership between AIM and CAN Health establishes a framework for the two organizations to identify opportunities, align clinical and operational expertise, and accelerate the evaluation and adoption of innovative technologies.

By connecting clinical insight, rigorous evaluation, and national pathways for adoption, the partnership aims to strengthen Canada’s health innovation ecosystem while ensuring that patients, providers and the broader economy benefit.

About Royal Columbian Hospital

As BC’s most comprehensive critical care hospital, one in three British Columbians rely on Royal Columbian Hospital. We are the only hospital in BC with trauma, cardiac, neurosciences, high-risk obstetrics and neonatal intensive care on one site. We look after some of the most seriously ill and injured patients, and we do it with the support of donors like you.

Since 1978, donors to Royal Columbian Hospital Foundation have helped fund priority equipment needs, facility enhancements, research, education and innovation at Royal Columbian Hospital. Visit rchfoundation.com for more information.

As part of Royal Columbian Hospital Foundation, the AIM Institute is a social enterprise that partners with innovative health-tech companies, providing clinical insights grounded in deep expertise, alongside clinical trial design and execution.

About the CAN Health Network

The Coordinated Accessible National (CAN) Health Network is a federally supported, not-for-profit organization that works with health care operators across Canada to identify challenges, validate Canadian innovations in real-world settings, and support procurement and scale. Since its launch in 2019, CAN Health has supported commercialization projects with more than 100 Canadian companies, helping strengthen health care delivery while driving economic growth.

CONTACT: For more information, please contact:
Jason Howe
Vice President, Marketing and Communications
C: 236.332.0798
Jason.Howe@fraserhealth.ca

Jennifer Coulman
Manager, Communications
CAN Health Network
jennifer.coulman@canhealthnetwork.ca

Cosmos Health Provides Update; Evaluates Options to Address Valuation Disconnect; Will Issue Updated Guidance Following FY 2025 Results; Record Growth Continues as Significant U.S. Expansion Underway, with Additional $12M+ in High-Margin Revenue Projected; Important R&D Updates Expected Following Finalization of Certain Anticipated Transactions




Cosmos Health Provides Update; Evaluates Options to Address Valuation Disconnect; Will Issue Updated Guidance Following FY 2025 Results; Record Growth Continues as Significant U.S. Expansion Underway, with Additional $12M+ in High-Margin Revenue Projected; Important R&D Updates Expected Following Finalization of Certain Anticipated Transactions

• Continues to deliver record revenue and improving operating metrics
• Significant expansion in the United States underway, with NOOR and other Sky Premium Life products expected to drive strong profitability
  • supported by gross margins of approximately 75%
  • NOOR Collagen alone is projected to generate more than $12 million in annualized revenue
• Strong growth expected ahead, driven by organic progress and M&A pipeline
  • including a recent LOI to acquire an $11.5 million pharmacy distribution network
• Holds valuable non-core strategic real estate and digital assets with an estimated fair market value exceeding $18 million, providing meaningful balance sheet flexibility
• Evaluating potential monetization of non-core assets to
  • support more efficient capital allocation
  • accelerate strategic investments
  • address the current valuation disconnect, including options such as share repurchases
• Recent geopolitical turmoil has had a negligible impact on the Company’s operations, with record-breaking growth continuing at a strong pace
• To issue guidance update following the release of fourth quarter and full-year 2025 results
• Analyst coverage initiated by Zacks Small-Cap Research with a valuation of $4.50 per share

CHICAGO, March 19, 2026 (GLOBE NEWSWIRE) — Cosmos Health Inc. (“Cosmos Health” or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today provided a corporate update and announced that it intends to issue updated operational, strategic, and financial guidance following the release of its fourth quarter and full-year 2025 financial results.

Record Operating Momentum
Cosmos Health continues to deliver record revenue and gross profit while improving operating metrics, reflecting disciplined execution across all core divisions. Management believes the Company is progressing toward sustained profitability as revenue continues to grow, scale efficiencies crystallize, and margins improve.

The war in the Middle East and recent geopolitical turmoil have had a negligible impact on the Company’s operations. The Company expects record-breaking growth to continue at a strong pace as it advances toward sustained profitability.

Strong Growth Amid Significant U.S. Expansion & Partnerships with Leading Retailers
Recent milestones include the continued global expansion of the Company’s proprietary brands. Sky Premium Life is growing across Europe and beyond. Importantly, the Company has recently entered the United States market with its NOOR and other Sky Premium Life products.

All NOOR Sky Premium Life products sold in the United States are manufactured locally in GMP-certified, FDA-registered, and UL-audited U.S. facilities, underscoring the Company’s commitment to regulatory excellence and product integrity while mitigating tariff exposure and cross-border logistical risks.

Cosmos Health anticipates strong gross margins of approximately 75% and significant cash flow generation from its Sky Premium Life U.S. operations. NOOR Collagen alone is projected to generate more than $12 million in annualized revenue, with additional growth expected as the Company introduces new products and expands its Sky Premium Life portfolio in the U.S. to meet strong consumer demand.

C-Scrub is gaining commercial validation in the United Kingdom through expanded retail presence at Tesco, the UK’s largest retailer, and Superdrug, the UK’s second-largest beauty and health retailer.

The Company’s contract manufacturing division continues to expand through new long-term agreements, while its wholesale logistics operations are serving increasing volumes across a growing pharmacy network.

R&D at the Forefront of Innovation
Cosmos Health continues to advance its R&D pipeline, further strengthened by the recent appointment of Dr. Dimitrios Iliopoulos, a globally recognized expert in AI-driven drug discovery and clinical-stage biotechnology, to its Advisory Board.

The Company expects to provide updates regarding significant progress across several R&D initiatives following the finalization of certain anticipated transactions.

M&A Pipeline
On March 6, 2026, Cosmos Health entered into a Letter of Intent to acquire an extensive pharmacy distribution network from an established pharmaceutical company serving the Greek market for almost 40 years. The network currently generates approximately $11.5 million in annual gross revenue and serves a broad base of pharmacy customers, supplying both pharmaceutical and para-pharmaceutical products.

In addition, the Company is actively evaluating a robust pipeline of acquisition opportunities designed to expand its distribution footprint, enhance operating scale, and drive profitability.

Balance Sheet Flexibility: $18 Million in Non-Core Assets
In addition to its core healthcare operating segments, the Company holds valuable non-core strategic assets that provide meaningful balance sheet flexibility. Among others, the Company owns real estate assets with an estimated fair market value of approximately $15 million and has also deployed $3.1 million into digital assets under its treasury strategy.

Zacks Coverage Initiated with $4.50 Per Share Valuation
Zacks Small-Cap Research initiated coverage on the Company with a valuation of $4.50 per share, according to a research report published on January 13, 2026. The report highlights Cosmos Health’s diversified revenue base, vertically integrated pharmaceutical and manufacturing operations, technology-driven initiatives, expansion into the U.S. market, and improving financial performance as key factors supporting its valuation.

Capital Allocation Considerations Amid Valuation Disconnect
At current trading levels, the Company’s shares trade at a significant discount to reported book value (stockholders’ equity), and management believes the Company’s market capitalization does not fully reflect the intrinsic value of its diversified asset base and strong operating performance.

While management recognizes the long-term strategic value of its real estate and digital asset holdings, it is also evaluating potential monetization options, subject to market conditions, that could generate substantial capital to address the current valuation disconnect and support key corporate priorities, including acquisitions, technology investments, debt reduction, and returning capital to shareholders, including share repurchases.

Greg Siokas, CEO of Cosmos Health, stated: “Our operating performance remains strong, with record revenue, improving profitability metrics, and an important expansion in the United States already underway with local manufacturing capabilities. At the same time, our balance sheet provides meaningful flexibility through a diversified asset base that includes non-core assets such as wholly owned real estate and digital holdings with a collective fair market value potentially exceeding $18 million. This represents a significant amount relative to our current market capitalization.

To provide greater visibility and a clear roadmap for investors, we intend to issue updated guidance on our operational, strategic, and financial outlook following our FY 2025 results and outline the next phase of our strategic priorities designed to enhance long-term shareholder value. Given current valuation levels, we are also evaluating capital allocation alternatives, including share repurchases.”

About Cosmos Health Inc.

Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, www.cloudscreen.gr, as well as LinkedIn and X.

Forward-Looking Statements
With the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans,” and similar expressions, or future or conditional verbs such as “will,” “should,” “would,” “may,” and “could,” generally identify forward-looking statements, although not all forward-looking statements contain these words. These statements involve risks and uncertainties that may individually or materially affect the matters discussed herein for a variety of reasons outside the Company’s control, including, but not limited to: the Company’s ability to raise sufficient financing to implement its business plan; the effectiveness of its digital asset strategies, including accumulation and yield-generating activities; the impact of the war in Ukraine on the Company’s business, operations, and the economy in general; and the Company’s ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results could differ materially from those anticipated. Readers are encouraged to review the risk factors set forth in the Company’s filings with the SEC, which are available at the SEC’s website (www.sec.gov). The Company disclaims any obligation to update or revise forward-looking statements, whether as a result of any new information, future events, or otherwise.

Investor Relations Contact:
BDG Communications
cosm@bdgcommunications.com

New partnership to fast-track Canadian health technology from innovation to patient care




New partnership to fast-track Canadian health technology from innovation to patient care

AIM Institute and CAN Health Network join forces to help 
Canadian solutions reach clinicians and patients faster

NEW WESTMINSTER, British Columbia, March 19, 2026 (GLOBE NEWSWIRE) — Royal Columbian Hospital Foundation’s AIM Institute (Advancing Innovation in Medicine) has partnered with the CAN Health Network to collaborate in supporting and scaling promising Canadian health technologies – helping patients benefit sooner from made-in-Canada solutions.

This collaboration brings together two Canadian organizations with a shared commitment to strengthening patient care through innovation. By aligning AIM’s clinical expertise and trial infrastructure with the CAN Health Network’s national network of health care operators and procurement pathways, the partnership is designed to help Canadian health-tech companies move faster from idea to validated solution, and ultimately to broader adoption across Canada.

Canadian health-tech companies will benefit from access to user-defined clinical challenges, direct engagement with frontline clinicians, rigorous clinical trial design and execution, and real-world product evaluation. The goal is to ensure that new solutions are not only innovative, but also clinically validated, economically viable, and ready for scale within Canada’s health care system.

As a social enterprise of Royal Columbian Hospital Foundation, AIM Institute partners with health-tech innovators at every stage of development, from early clinical guidance to multi-centre trials and real-world implementation. Its work is grounded in the belief that improving patient care and achieving commercial success are intrinsically linked.

The CAN Health Network connects healthcare organizations across the country through an integrated market to identify challenges, validate Canadian solutions in real-world settings, and support procurement and scale. Since its launch in 2019, CAN Health has supported commercialization projects with more than 100 Canadian companies, helping strengthen health care delivery while driving economic growth.

“Working alongside the CAN Health Network allows us to help promising Canadian technologies move more efficiently from concept to real-world use,” says Dr. Steve Reynolds, Royal Columbian Hospital ICU physician and AIM Executive Lead. “This helps ensure that solutions developed here can ultimately improve care for patients and support healthcare teams across the country and beyond.”

“The most powerful health care solutions come from solving real problems faced by patients and providers,” said Dante Morra, Founder & CEO, CAN Health Network. “By connecting innovators with frontline health care environments through the AIM Institute, we can test, validate and scale Canadian solutions faster, improving care while helping Canadian companies grow and succeed.”

This partnership between AIM and CAN Health establishes a framework for the two organizations to identify opportunities, align clinical and operational expertise, and accelerate the evaluation and adoption of innovative technologies.

By connecting clinical insight, rigorous evaluation, and national pathways for adoption, the partnership aims to strengthen Canada’s health innovation ecosystem while ensuring that patients, providers and the broader economy benefit.

About Royal Columbian Hospital

As BC’s most comprehensive critical care hospital, one in three British Columbians rely on Royal Columbian Hospital. We are the only hospital in BC with trauma, cardiac, neurosciences, high-risk obstetrics and neonatal intensive care on one site. We look after some of the most seriously ill and injured patients, and we do it with the support of donors like you.

Since 1978, donors to Royal Columbian Hospital Foundation have helped fund priority equipment needs, facility enhancements, research, education and innovation at Royal Columbian Hospital. Visit rchfoundation.com for more information.

As part of Royal Columbian Hospital Foundation, the AIM Institute is a social enterprise that partners with innovative health-tech companies, providing clinical insights grounded in deep expertise, alongside clinical trial design and execution.

About the CAN Health Network

The Coordinated Accessible National (CAN) Health Network is a federally supported, not-for-profit organization that works with health care operators across Canada to identify challenges, validate Canadian innovations in real-world settings, and support procurement and scale. Since its launch in 2019, CAN Health has supported commercialization projects with more than 100 Canadian companies, helping strengthen health care delivery while driving economic growth.

CONTACT: For more information, please contact:
Jason Howe
Vice President, Marketing and Communications
C: 236.332.0798
Jason.Howe@fraserhealth.ca

Jennifer Coulman
Manager, Communications
CAN Health Network
jennifer.coulman@canhealthnetwork.ca

The Endothelial Glycocalyx Explained: How It Helps Regulate Vascular Function




The Endothelial Glycocalyx Explained: How It Helps Regulate Vascular Function

• The Endothelial Glycocalyx Is a Gel-Like Lining Inside Every Blood Vessel — and Most People Have Never Heard of It
• Standard Cardiovascular Screenings Focus on Large Arteries but Do Not Assess What Is Happening at the Microvascular Level
• How Published Research and Patented Lab-on-a-Chip Technology Are Advancing What We Know About Glycocalyx Function
• Why Lifestyle Factors Like Diet, Movement, and Targeted Supplementation May Help Maintain Glycocalyx Integrity

Scottsdale, AZ, March 19, 2026 (GLOBE NEWSWIRE) — Calroy Health Sciences, a science-driven dietary supplement company focused on foundational health, has published a comprehensive educational resource exploring the role of the endothelial glycocalyx (EGX) in everyday circulation. The article, Microcirculation and Blood Flow: The Missing Link Between How You Feel Every Day and the Endothelial Glycocalyx, provides an accessible overview of the science behind a vascular structure most people have never heard of.

Dr. Joel Kahn, MD, integrative cardiologist, founder of the Kahn Center for Cardiac Longevity in Bingham Farms, Michigan, and frequent educator for Calroy, explains: “The glycocalyx is a gel-like lining inside every blood vessel. When it’s intact, blood flows the way it should. When it thins, the body feels it — even before standard tests pick anything up.”

KEY FACTS

• The endothelial glycocalyx is a delicate, micro-thin, gel-like lining that coats the inside of every blood vessel, helping regulate vascular function throughout the body, including at the microvascular level.
• Research published in the National Library of Medicine has identified vascular elasticity as a marker of endothelial function (PubMed: 28356037).
• The EGX plays a functional role in supporting the movement of nutrients and oxygen from blood vessels into surrounding tissue.
• Most routine cardiovascular screenings focus on large arteries and do not assess endothelial glycocalyx integrity or microvascular function.
• Calroy Health Sciences utilizes patented microfluidic chip technology to simulate vascular conditions in a lab-on-a-chip environment to study endothelial glycocalyx behavior.
• MonitumRS®, a proprietary extract of Rhamnan sulfate from Monostroma nitidum, is scientifically shown to protect and restore the endothelial glycocalyx.*†

The Endothelial Glycocalyx Is a Gel-Like Lining Inside Every Blood Vessel — and Most People Have Never Heard of It

The endothelial glycocalyx is one of the most important structures in the vascular system — and one of the least discussed. This delicate, micro-thin lining coats the interior of every blood vessel in the body, from the largest arteries to the smallest capillaries. Only recently discovered and often overlooked, it is foundational to vascular health and total-body vitality. The EGX acts as a semi-permeable barrier, facilitates smooth blood flow, and houses the enzymes involved in nitric oxide production — the molecule that helps blood vessels relax and support healthy circulation.*

When the glycocalyx is intact, blood flow at the microvascular level proceeds efficiently. Maintaining glycocalyx integrity supports efficient nutrient delivery and vascular responsiveness at the capillary level. The Calroy Health Sciences education center provides a detailed introduction to how the glycocalyx functions within the broader circulatory system.

Standard Cardiovascular Screenings Focus on Large Arteries but Do Not Assess What Is Happening at the Microvascular Level

Most cardiovascular assessments focus on large-vessel metrics — arterial imaging and standard panels that evaluate the body’s primary supply routes. These tools are valuable, but they do not evaluate what is happening at the microvascular level. The glycocalyx exists in the smallest blood vessels — the capillaries — where nutrient exchange actually occurs. This means a person can receive clear results from standard vascular screenings while their microcirculation tells a different story.

A peer-reviewed study available through the National Library of Medicine found that vascular elasticity markers can serve as early indicators of endothelial function, suggesting that tools beyond standard panels may be needed to understand full circulatory health. Calroy’s proprietary microfluidic chip technology was developed to help address this gap by simulating vascular conditions in a controlled lab-on-a-chip environment.

How Published Research and Patented Lab-on-a-Chip Technology Are Advancing What We Know About Glycocalyx Function

Calroy Health Sciences has built research around a simple question: can the glycocalyx be supported through targeted nutritional science? The company’s approach combines published peer-reviewed research with proprietary technology. Its research library includes studies on Rhamnan sulfate, nitric oxide pathways, and cartilage support.

Dr. Kahn notes: “What makes the glycocalyx conversation so important is that it connects how people feel every day — their energy, their clarity, their recovery — to a structure that science can study and support.”

The company’s Science and Medical Advisory Board includes physicians, researchers, and practitioners who guide product development and ensure claims are rooted in published science.

Why Lifestyle Factors Like Diet, Movement, and Targeted Supplementation May Help Maintain Glycocalyx Integrity

The glycocalyx is a structure to support — and lifestyle factors including diet, movement, hydration, and targeted supplementation all play a role in maintaining glycocalyx integrity. Calroy’s educational approach emphasizes that an antioxidant-dense diet, regular movement, healthy sleep routines, and mindfulness all contribute to overall wellness and vascular well-being. The company’s flagship product, Arterosil HP® with MonitumRS®, supports vascular integrity and healthy circulation.*

MonitumRS is scientifically shown to protect and restore the endothelial glycocalyx.*† Additional resources on EGX science are available at Calroy’s introduction to the endothelial glycocalyx and through practitioner-focused research on the EGX.

FREQUENTLY ASKED QUESTIONS

Why do I still feel tired even though my blood work is normal? 

Standard panels assess large-vessel markers but do not always evaluate microvascular function or glycocalyx integrity. Reduced blood flow at the capillary level — where oxygen and nutrient exchange actually happens — may affect energy and recovery even when routine screenings come back with clear results.

What is microcirculation and why does it matter? 

Microcirculation is the movement of blood through your smallest vessels — the capillaries. It’s where your body actually delivers oxygen and nutrients to tissue. Just like  large-artery circulation, microcirculation is also influenced by a structure called the endothelial glycocalyx, which most people have never heard of. A detailed overview is available at calroy.com/education/microcirculation-and-blood-flow.

What does the lining of your blood vessels actually do? 

The endothelial glycocalyx is a delicate, micro-thin, gel-like lining that coats the interior of every blood vessel. It acts as a semi-permeable barrier, facilitates smooth blood flow, and houses the enzymes involved in nitric oxide production. When the glycocalyx is compromised, circulation is affected and every organ feels the impact.

Are there tests that measure how well blood flows in small blood vessels? 

Most standard cardiovascular screenings focus on large arteries and many don’t assess microvascular function. Emerging research, including a peer-reviewed study on vascular elasticity markers (PubMed: 28356037), suggests that new tools may be needed to evaluate what’s happening at the capillary level.

Can what you eat affect your blood vessels?

Yes. Lifestyle factors including diet, hydration, movement, and healthy sleep routines can influence the integrity of the vascular system and likely the endothelial glycocalyx — the structure that lines every blood vessel and supports microcirculation. An antioxidant-rich diet and regular movement support cardiovascular and overall health.*

What supplements actually help with circulation? 

The endothelial glycocalyx is the micro-thin lining inside every blood vessel where blood flow regulation begins at the capillary level. Arterosil HP® with MonitumRS® supports vascular integrity and healthy circulation.* MonitumRS is scientifically shown to protect and restore the endothelial glycocalyx.*† 

What is the difference between arteries and capillaries? 

Arteries carry blood away from the heart through large vessels. Capillaries are the smallest vessels where the actual exchange of oxygen, nutrients, and waste occurs at the tissue level. The endothelial glycocalyx plays a key role in regulating the entire vascular system, including large arteries and tiny capillaries.

PUBLISHED RESEARCH & RESOURCES

• Research on the Endothelial Glycocalyx — Practitioner Resources
• Research on Rhamnan Sulfate from Monostroma Nitidum — Practitioner Resources
• Research on Nitric Oxide and the Vascular System — Practitioner Resources
• Markers of Vascular Elasticity and Endothelial Integrity — PubMed
• Calroy’s Published Research — Calroy Health Sciences
• Calroy’s Patents — Calroy Health Sciences
• Science and Medical Advisory Board — Calroy Health Sciences
• Quarterly Anchor Article — Calroy Health Sciences

About Calroy Health Sciences

Calroy Health Sciences is a science-driven dietary supplement company dedicated to supporting foundational health. Co-founded by CEO Ed Hoyt and Chief Scientific Officer Chen Chen, PhD, Calroy brings more than three decades of combined experience in the dietary supplement industry. The company’s breakthrough products — Arterosil HP® with MonitumRS®, Vascanox HP® with Noxa24®, and Cartigenix HP® with RestorCel™ — are developed through a research-first approach that includes studying the finished formulated product, not just individual ingredients. 

Calroy’s research has been published in peer-reviewed journals and is conducted in partnership with major academic institutions, leading clinicians and researchers. The company also holds patents on its products and its microfluidic chip testing technology. For more information, visit calroy.com.

SME Available for Commentary: Joel Kahn, MD — Integrative Cardiologist, Kahn Center for Cardiac Longevity

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

†As demonstrated in an independent third-party laboratory in vitro study.Scottsdale, AZ, March 19, 2026 (GLOBE NEWSWIRE) —

CONTACT: Sarah Evans
Partner, Head of PR, Zen Media
sarah@zenmedia.com

OKYO Pharma Announces Chairman and Founder Acquires Shares




OKYO Pharma Announces Chairman and Founder Acquires Shares

LONDON and NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) — OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced it has been informed that Panetta Partners Limited, an entity in which Gabriele Cerrone, the Executive Chairman, has a beneficial interest, has acquired 10,119 of the Company’s ordinary shares on NASDAQ at $1.59, bringing his total holding to 10,526,416 shares.

About Urcosimod (formerly called OK-101)

Urcosimod is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of the eye responsible for the inflammatory response, as well as on neurons and glial cells in the dorsal root ganglion. Urcosimod has been shown to produce anti-inflammatory and pain-reducing activities in a mouse model of dry eye disease and in a neuropathic corneal pain mouse model, respectively. OKYO recently announced positive data on NCP pain reduction in a randomized, placebo-controlled, double-masked Phase 2a trial involving 18 neuropathic corneal pain subjects. Urcosimod has shown significant pain reduction in an earlier 240 subject Phase 2, multi-center, double-masked, placebo-controlled trial in DED, which supports the development rationale in NCP.

About OKYO Pharma

OKYO Pharma Limited (Nasdaq: OKYO) is a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP) and inflammatory eye diseases, with ordinary shares listed for trading on the Nasdaq Capital Market. OKYO is focused on the discovery and development of novel molecules to treat neuropathic corneal pain and other ocular diseases. OKYO recently completed a successful phase 2 trial of its flagship drug urcosimod in subjects with NCP and plans to initiate a ~150 subject Phase 2b/3 multiple-dose study of urcosimod to treat NCP in the first half of this year.

For further information, please visit www.okyopharma.com.

Inquiries:

The Endothelial Glycocalyx Explained: How It Helps Regulate Vascular Function




The Endothelial Glycocalyx Explained: How It Helps Regulate Vascular Function

• The Endothelial Glycocalyx Is a Gel-Like Lining Inside Every Blood Vessel — and Most People Have Never Heard of It
• Standard Cardiovascular Screenings Focus on Large Arteries but Do Not Assess What Is Happening at the Microvascular Level
• How Published Research and Patented Lab-on-a-Chip Technology Are Advancing What We Know About Glycocalyx Function
• Why Lifestyle Factors Like Diet, Movement, and Targeted Supplementation May Help Maintain Glycocalyx Integrity

Scottsdale, AZ, March 19, 2026 (GLOBE NEWSWIRE) — Calroy Health Sciences, a science-driven dietary supplement company focused on foundational health, has published a comprehensive educational resource exploring the role of the endothelial glycocalyx (EGX) in everyday circulation. The article, Microcirculation and Blood Flow: The Missing Link Between How You Feel Every Day and the Endothelial Glycocalyx, provides an accessible overview of the science behind a vascular structure most people have never heard of.

Dr. Joel Kahn, MD, integrative cardiologist, founder of the Kahn Center for Cardiac Longevity in Bingham Farms, Michigan, and frequent educator for Calroy, explains: “The glycocalyx is a gel-like lining inside every blood vessel. When it’s intact, blood flows the way it should. When it thins, the body feels it — even before standard tests pick anything up.”

KEY FACTS

• The endothelial glycocalyx is a delicate, micro-thin, gel-like lining that coats the inside of every blood vessel, helping regulate vascular function throughout the body, including at the microvascular level.
• Research published in the National Library of Medicine has identified vascular elasticity as a marker of endothelial function (PubMed: 28356037).
• The EGX plays a functional role in supporting the movement of nutrients and oxygen from blood vessels into surrounding tissue.
• Most routine cardiovascular screenings focus on large arteries and do not assess endothelial glycocalyx integrity or microvascular function.
• Calroy Health Sciences utilizes patented microfluidic chip technology to simulate vascular conditions in a lab-on-a-chip environment to study endothelial glycocalyx behavior.
• MonitumRS®, a proprietary extract of Rhamnan sulfate from Monostroma nitidum, is scientifically shown to protect and restore the endothelial glycocalyx.*†

The Endothelial Glycocalyx Is a Gel-Like Lining Inside Every Blood Vessel — and Most People Have Never Heard of It

The endothelial glycocalyx is one of the most important structures in the vascular system — and one of the least discussed. This delicate, micro-thin lining coats the interior of every blood vessel in the body, from the largest arteries to the smallest capillaries. Only recently discovered and often overlooked, it is foundational to vascular health and total-body vitality. The EGX acts as a semi-permeable barrier, facilitates smooth blood flow, and houses the enzymes involved in nitric oxide production — the molecule that helps blood vessels relax and support healthy circulation.*

When the glycocalyx is intact, blood flow at the microvascular level proceeds efficiently. Maintaining glycocalyx integrity supports efficient nutrient delivery and vascular responsiveness at the capillary level. The Calroy Health Sciences education center provides a detailed introduction to how the glycocalyx functions within the broader circulatory system.

Standard Cardiovascular Screenings Focus on Large Arteries but Do Not Assess What Is Happening at the Microvascular Level

Most cardiovascular assessments focus on large-vessel metrics — arterial imaging and standard panels that evaluate the body’s primary supply routes. These tools are valuable, but they do not evaluate what is happening at the microvascular level. The glycocalyx exists in the smallest blood vessels — the capillaries — where nutrient exchange actually occurs. This means a person can receive clear results from standard vascular screenings while their microcirculation tells a different story.

A peer-reviewed study available through the National Library of Medicine found that vascular elasticity markers can serve as early indicators of endothelial function, suggesting that tools beyond standard panels may be needed to understand full circulatory health. Calroy’s proprietary microfluidic chip technology was developed to help address this gap by simulating vascular conditions in a controlled lab-on-a-chip environment.

How Published Research and Patented Lab-on-a-Chip Technology Are Advancing What We Know About Glycocalyx Function

Calroy Health Sciences has built research around a simple question: can the glycocalyx be supported through targeted nutritional science? The company’s approach combines published peer-reviewed research with proprietary technology. Its research library includes studies on Rhamnan sulfate, nitric oxide pathways, and cartilage support.

Dr. Kahn notes: “What makes the glycocalyx conversation so important is that it connects how people feel every day — their energy, their clarity, their recovery — to a structure that science can study and support.”

The company’s Science and Medical Advisory Board includes physicians, researchers, and practitioners who guide product development and ensure claims are rooted in published science.

Why Lifestyle Factors Like Diet, Movement, and Targeted Supplementation May Help Maintain Glycocalyx Integrity

The glycocalyx is a structure to support — and lifestyle factors including diet, movement, hydration, and targeted supplementation all play a role in maintaining glycocalyx integrity. Calroy’s educational approach emphasizes that an antioxidant-dense diet, regular movement, healthy sleep routines, and mindfulness all contribute to overall wellness and vascular well-being. The company’s flagship product, Arterosil HP® with MonitumRS®, supports vascular integrity and healthy circulation.*

MonitumRS is scientifically shown to protect and restore the endothelial glycocalyx.*† Additional resources on EGX science are available at Calroy’s introduction to the endothelial glycocalyx and through practitioner-focused research on the EGX.

FREQUENTLY ASKED QUESTIONS

Why do I still feel tired even though my blood work is normal? 

Standard panels assess large-vessel markers but do not always evaluate microvascular function or glycocalyx integrity. Reduced blood flow at the capillary level — where oxygen and nutrient exchange actually happens — may affect energy and recovery even when routine screenings come back with clear results.

What is microcirculation and why does it matter? 

Microcirculation is the movement of blood through your smallest vessels — the capillaries. It’s where your body actually delivers oxygen and nutrients to tissue. Just like  large-artery circulation, microcirculation is also influenced by a structure called the endothelial glycocalyx, which most people have never heard of. A detailed overview is available at calroy.com/education/microcirculation-and-blood-flow.

What does the lining of your blood vessels actually do? 

The endothelial glycocalyx is a delicate, micro-thin, gel-like lining that coats the interior of every blood vessel. It acts as a semi-permeable barrier, facilitates smooth blood flow, and houses the enzymes involved in nitric oxide production. When the glycocalyx is compromised, circulation is affected and every organ feels the impact.

Are there tests that measure how well blood flows in small blood vessels? 

Most standard cardiovascular screenings focus on large arteries and many don’t assess microvascular function. Emerging research, including a peer-reviewed study on vascular elasticity markers (PubMed: 28356037), suggests that new tools may be needed to evaluate what’s happening at the capillary level.

Can what you eat affect your blood vessels?

Yes. Lifestyle factors including diet, hydration, movement, and healthy sleep routines can influence the integrity of the vascular system and likely the endothelial glycocalyx — the structure that lines every blood vessel and supports microcirculation. An antioxidant-rich diet and regular movement support cardiovascular and overall health.*

What supplements actually help with circulation? 

The endothelial glycocalyx is the micro-thin lining inside every blood vessel where blood flow regulation begins at the capillary level. Arterosil HP® with MonitumRS® supports vascular integrity and healthy circulation.* MonitumRS is scientifically shown to protect and restore the endothelial glycocalyx.*† 

What is the difference between arteries and capillaries? 

Arteries carry blood away from the heart through large vessels. Capillaries are the smallest vessels where the actual exchange of oxygen, nutrients, and waste occurs at the tissue level. The endothelial glycocalyx plays a key role in regulating the entire vascular system, including large arteries and tiny capillaries.

PUBLISHED RESEARCH & RESOURCES

• Research on the Endothelial Glycocalyx — Practitioner Resources
• Research on Rhamnan Sulfate from Monostroma Nitidum — Practitioner Resources
• Research on Nitric Oxide and the Vascular System — Practitioner Resources
• Markers of Vascular Elasticity and Endothelial Integrity — PubMed
• Calroy’s Published Research — Calroy Health Sciences
• Calroy’s Patents — Calroy Health Sciences
• Science and Medical Advisory Board — Calroy Health Sciences
• Quarterly Anchor Article — Calroy Health Sciences

About Calroy Health Sciences

Calroy Health Sciences is a science-driven dietary supplement company dedicated to supporting foundational health. Co-founded by CEO Ed Hoyt and Chief Scientific Officer Chen Chen, PhD, Calroy brings more than three decades of combined experience in the dietary supplement industry. The company’s breakthrough products — Arterosil HP® with MonitumRS®, Vascanox HP® with Noxa24®, and Cartigenix HP® with RestorCel™ — are developed through a research-first approach that includes studying the finished formulated product, not just individual ingredients. 

Calroy’s research has been published in peer-reviewed journals and is conducted in partnership with major academic institutions, leading clinicians and researchers. The company also holds patents on its products and its microfluidic chip testing technology. For more information, visit calroy.com.

SME Available for Commentary: Joel Kahn, MD — Integrative Cardiologist, Kahn Center for Cardiac Longevity

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

†As demonstrated in an independent third-party laboratory in vitro study.Scottsdale, AZ, March 19, 2026 (GLOBE NEWSWIRE) —

CONTACT: Sarah Evans
Partner, Head of PR, Zen Media
sarah@zenmedia.com

OKYO Pharma Announces Chairman and Founder Acquires Shares




OKYO Pharma Announces Chairman and Founder Acquires Shares

LONDON and NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) — OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced it has been informed that Panetta Partners Limited, an entity in which Gabriele Cerrone, the Executive Chairman, has a beneficial interest, has acquired 10,119 of the Company’s ordinary shares on NASDAQ at $1.59, bringing his total holding to 10,526,416 shares.

About Urcosimod (formerly called OK-101)

Urcosimod is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of the eye responsible for the inflammatory response, as well as on neurons and glial cells in the dorsal root ganglion. Urcosimod has been shown to produce anti-inflammatory and pain-reducing activities in a mouse model of dry eye disease and in a neuropathic corneal pain mouse model, respectively. OKYO recently announced positive data on NCP pain reduction in a randomized, placebo-controlled, double-masked Phase 2a trial involving 18 neuropathic corneal pain subjects. Urcosimod has shown significant pain reduction in an earlier 240 subject Phase 2, multi-center, double-masked, placebo-controlled trial in DED, which supports the development rationale in NCP.

About OKYO Pharma

OKYO Pharma Limited (Nasdaq: OKYO) is a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP) and inflammatory eye diseases, with ordinary shares listed for trading on the Nasdaq Capital Market. OKYO is focused on the discovery and development of novel molecules to treat neuropathic corneal pain and other ocular diseases. OKYO recently completed a successful phase 2 trial of its flagship drug urcosimod in subjects with NCP and plans to initiate a ~150 subject Phase 2b/3 multiple-dose study of urcosimod to treat NCP in the first half of this year.

For further information, please visit www.okyopharma.com.

Inquiries:

Novo Nordisk A/S: Wegovy® HD (semaglutide 7.2 mg) approved in the US, providing 20.7% mean weight loss




Novo Nordisk A/S: Wegovy® HD (semaglutide 7.2 mg) approved in the US, providing 20.7% mean weight loss

• Wegovy^® HD demonstrated a mean weight loss of 20.7%¹, and around one-third of patients achieved 25% or greater weight loss in the STEP UP trial
• First US FDA approval of a GLP-1 treatment under the Commissioner’s National Priority Voucher pilot programme, for products addressing critical US national health priorities
• Wegovy^® HD complements Wegovy^® 2.4 mg, which is already approved in the US for weight management and cardiovascular risk reduction
• Novo Nordisk expects to launch Wegovy^® HD in the US in April 2026

Bagsværd, Denmark, 19 March 2026 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved Wegovy^® HD (once-weekly injectable semaglutide 7.2 mg) to reduce excess body weight and maintain weight reduction long-term. The FDA awarded a Commissioner’s National Priority Voucher for Wegovy^® HD, accelerating its review and underscoring its potential to address critical patient needs and national health priorities in the US.

The accelerated approval is based on results from the STEP UP trial programme. In the STEP UP trial, semaglutide 7.2 mg injected once weekly demonstrated 20.7%¹ mean weight loss in participants with obesity, and approximately one in three people experienced 25% or greater weight loss. In the STEP UP type 2 diabetes (T2D) trial, in participants with obesity and type 2 diabetes, semaglutide 7.2 mg demonstrated a mean weight loss of 14.1%¹. In both trials, the well-known safety and tolerability profile of semaglutide was reaffirmed with semaglutide 7.2 mg, which was comparable to previous trials with semaglutide for weight management.

“Since its launch in 2021, Wegovy^® has transformed the lives of many people living with obesity and helped them achieve meaningful weight loss and important cardiometabolic benefits, including an unprecedented reduction in cardiovascular risk,” said Mike Doustdar, president and CEO of Novo Nordisk. “Earlier this year, we launched the Wegovy^® pill, and with the accelerated approval of Wegovy^® HD, we are introducing a new offering for our injectable semaglutide that provides even greater weight loss of approximately 21%. At Novo Nordisk, our goal is to provide innovative therapies that support healthier lives for people living with obesity, and we look forward to launching Wegovy^® HD to help even more people reach their weight and health goals.”

Novo Nordisk expects to launch Wegovy^® HD in a single-dose pen in the US in April 2026.

Wegovy^® 7.2 mg is already approved for adults with obesity in the EU and the UK. Novo Nordisk expects regulatory decisions in the EU and the UK on semaglutide 7.2 mg in a single-dose pen in the second half of 2026.

About the STEP UP trials
The STEP UP and STEP UP T2D phase 3 trials investigated the efficacy and safety of injectable semaglutide 7.2 mg in people with obesity with or without type 2 diabetes.

The 72-week STEP UP trial evaluated the efficacy and safety of injectable semaglutide 7.2 mg compared to semaglutide 2.4 mg and placebo as an adjunct to lifestyle intervention. The trial included approximately 1,400 adults with obesity. The 72-week STEP UP T2D trial evaluated the efficacy and safety of injectable semaglutide 7.2 mg compared to placebo in approximately 500 adults with obesity and type 2 diabetes.

^* Treatment effect if all people adhered to treatment, ^** Treatment effect regardless of treatment adherence

About Wegovy^®
Wegovy^® is approved as once-daily Wegovy^® pill (semaglutide tablet 25 mg) and once-weekly Wegovy^® injections (semaglutide 1.7 mg, 2.4 mg and 7.2 mg) by the FDA.

Wegovy^® is approved as a once-weekly injection by the EMA and by other regulatory authorities worldwide. The Wegovy^® pill is currently pending marketing approval from the EMA and other regulatory authorities.

Wegovy^® is indicated to reduce excess body weight and maintain weight reduction long term in adults with obesity or overweight and in the presence of at least one weight-related comorbid condition, and approved by the FDA to reduce the risk of major adverse cardiovascular events, such as death, heart attack or stroke in adults with known heart disease and either obesity or overweight. Furthermore, Wegovy^® injection is indicated to reduce excess body weight and maintain long-term weight reduction in paediatric patients aged 12 years and older. It is approved by the FDA for the treatment of MASH in adults with moderate to advanced liver scarring (fibrosis), but not in those with cirrhosis of the liver.

About Novo Nordisk
Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 68,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk’s B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.

Publication of inside information pursuant to Market Abuse Regulation, Article 17.

Contacts for further information

Company announcement No 19 / 2026

¹ Based on the efficacy estimand: treatment effect if all people adhered to treatment

Attachment

• CA260319-Wegovy-HD-FDA-approval